Protective effects of insulin-like growth factor-I on the somatostatinergic system in the temporal cortex of β-amyloid-treated rats

Journal of Neurochemistry

Volumn 92, Issue 3, 2005, Pages 607-615

  Aguado Llera, D ^a   Arilla Ferreiro, E ^b   Campos Barros, A ^a   Puebla Jimenez L ^b   Barrios, Vicente ^a,c  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

amyloid; Alzheimer's disease; IGF I; Neuroprotection; Somatostatin; Somatostatin receptor subtypes

Indexed keywords

ADENYLATE CYCLASE; AMYLOID BETA PROTEIN[25-35]; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATE BINDING INHIBITORY PROTEIN ALPHA 1; GUANOSINE TRIPHOSPHATE BINDING INHIBITORY PROTEIN ALPHA 2; GUANOSINE TRIPHOSPHATE BINDING INHIBITORY PROTEIN ALPHA 3; PROTEIN KINASE B; PROTEIN SUBUNIT; SOMATOMEDIN C; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; ENZYME ACTIVITY; IMMUNOREACTIVITY; MALE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR DENSITY; SOMATOSTATINERGIC SYSTEM; TEMPORAL CORTEX;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BINDING, COMPETITIVE; CELL DEATH; DRUG ADMINISTRATION ROUTES; DRUG ANTAGONISM; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; INSULIN-LIKE GROWTH FACTOR I; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TEMPORAL LOBE;

ANIMALIA;

EID: 13244292389     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02889.x     Document Type: Article

References (55)

1. Abramov A. Y., Canevari L. and Duchen M. R. (2003) Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J. Neurosci. 23, 5088-5095.
2. Barton J. J. (2003) Disorders of face perception and recognition. Neurol. Clin. 21, 521-548.
3. Beal M. F., Mazurek M. F., Tran V. T., Chattha G., Bird E. D. and Martin J. B. (1985) Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease. Science 229, 289-291.
4. Bergstrom L., Garlind A., Nilsson L., Alafuzoff I., Fowler C. J., Winblad B. and Cowburn R. F. (1991) Regional distribution of somatostatin receptor binding and modulation of adenylyl cyclase activity in Alzheimer's disease brain. J. Neurol. Sci. 105, 225-233.
5. Bonkale W. L., Fastbom J., Wiehager B., Ravid R., Winblad B. and Cowburn R. F. (1996) Impaired G-protein-stimulated adenylyl cyclase activity in Alzheimer's disease brain is not accompanied by reduced cyclic-AMP-dependent protein kinase A activity. Brain Res. 737, 155-161.
6. Busiguina S., Fernández A. M., Barrios V., Clark R., Tolbert D. L., Berciano J. and Torres-Alemán I. (2000) Neurodegeneration is associated to changes in serum insulin-like growth factors. Neurobiol. Dis. 1, 657-665.
7. Carro E., Núñez A., Busiguina S. and Torres-Alemán I. (2000) Circulating insulin-like growth factor I mediates effects of exercise on the brain. J. Neurosci. 20, 2926-2933.
8. Carro E., Trejo J. L., Busiguina S. and Torres-Alemán I. (2001) Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. J. Neurosci. 21, 5678-5684.
9. Carro E., Trejo J. L., Gómez-Isla T., LeRoith D. and Torres-Alemán I. (2002) Serum insulin-like growth factor I regulates brain amyloid-β levels. Nat. Med. 8, 1390-1397.
10. Cowburn R. F., Fowler C. J., Garlind A., Alafuzoff I., Nilsson L., Winblad B. and Bergstrom L. (1991) Somatostatin receptors and the modulation of adenylyl cyclase activity in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 54, 748-749.
11. Cowburn R. F., O'Neill C., Bonkale W. L., Ohm T. G. and Fastbom J. (2001) Receptor-G-protein signalling in Alzheimer's disease. Biochem. Soc. Symp. 67, 163-175.
12. Czernik A. J. and Petrack V. (1983) Somatostatin receptor binding in rat cerebral cortex. Characterization using a nonreducible somatostatin analog. J. Biol. Chem. 285, 5525-5530.
13. Doré S., Kar S. and Quirion R. (1997) Insulin-like growth factor I protects and rescues hippocampal neurons against β-amyloid- and human amylin-induced toxicity. Proc. Natl Acad. Sci. USA 94, 4772-4777.
14. Dournaud P., Cervera-Pierot P., Hirsch E., Javoy-Agid F., Kordon C., Agid Y. and Epelbaum J. (1994) Somatostatin messenger RNA-containing neurons in Alzheimer's disease: an in situ hybridization study in hippocampus, parahippocampal cortex and frontal cortex. Neuroscience 61, 755-764.
15. Dudek H., Datta S. R., Franke T. F., Birnbaum M. J., Yao R., Cooper G. M., Segal R. A., Kaplan D. R. and Greenberg M. E. (1997) Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275, 661-665.
16. Fernández A. M., de la Vega A. G. and Torres-Alemán I. (1998) Insulin-like growth factor I restores motor coordination in a rat model of cerebellar ataxia. Proc. Natl Acad. Sci. USA 95, 1253-1258.
17. 3H]forskolin binding sites in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits. Brain Res. 850, 104-107.
18. Ghigo M. C., Torsello A., Grilli R., Luoni M., Guidi M., Cella S. G., Locatelli V. and Muller E. E. (1997) Effects of GH and IGF-I administration on GHRH and somatostatin mRNA levels: I. A study on ad libitum fed and starved adult male rats. J. Endocrinol. Invest. 20, 144-150.
19. Gilman A. G. (1970) A protein binding assay for adenosine 3′5′-cyclic monophosphate. Proc. Natl Acad. Sci. USA 67, 305-312.
20. 3H]DOPA in various regions of the brain. J. Neurochem. 13, 655-669.
21. 131I-labeled human growth hormone of high specific radioactivity. Biochem. J. 89, 114-123.
22. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F. and Cole G. (1996) Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99-103.
23. Hu W., Gray N. W. and Brimijoin S. (2003) Amyloid-β increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation. J. Neurochem. 86, 470-478.
24. Itoh A., Nitta A., Nadai M., Nishimura K., Hirose M., Hasegawa T. and Nabeshima T. (1996) Dysfunction of cholinergic and dopaminergic neuronal systems in β-amyloid protein-infused rats. J. Neurochem. 66, 1113-1117.
25. Jafferali S., Dumont Y., Sotty F., Robitaille Y., Quirion R. and Kar S. (2000) Insulin-like growth factor-I and its receptor in the frontal cortex, hippocampus, and cerebellum of normal human and Alzheimer disease brains. Synapse 38, 450-459.
26. Kienlen-Campard P., Miolet S., Tasiaux B. and Octave J. N. (2002) Intracellular amyloid-β 1-42, but not extracellular soluble amyloid-β peptides, induces neuronal apoptosis. J. Biol. Chem. 277, 15 666-15 670.
27. Kraus J., Wöltje M., Schönwetter N. and Höllt V. (2000) Gene structure and regulation of the somatostatin receptor type 2. J. Physiol. 94, 199-204.
28. Kubo T., Nishimura S., Kumagae Y. and Kaneko I. (2002) In vivo conversion of racemized β-amyloid ([D-Ser 26]Aβ 1-40) to truncated and toxic fragments ([D-Ser 26]Aβ 25-35/40) and fragment presence in the brains of Alzheimer's patients. J. Neurosci. Res. 70, 474-483.
29. Lowry O. H., Rosenbrough N. J., Farr A. L. and Randall R. J. (1951) Protein measurement with the folin phenol reagent. J. Biol. Chem. 193, 265-275.
30. Maurice T., Lockhart B. P., Su T. P. and Privat A. (1996) Reversion of β-amyloid peptide-induced amnesia by NMDA receptor-associated glycine site agonists. Brain Res. 731, 249-253.
31. Minthon L., Edvinsson L. and Gustafson L. (1997) Somatostatin and neuropeptide Y in cerebrospinal fluid: correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia. Dement. Geriatr. Cogn. Disord. 8, 232-239.
32. Movsesyan V. A., Stoica B. A. and Faden A. I. (2004) MGLuR5 activation reduces β-amyloid-induced cell death in primary neuronal cultures and attenuates translocation of cytochrome c and apoptosis-inducing factor. J. Neurochem. 89, 1528-1536.
33. Mumby S. M., Kahn R. A., Manning D. R. and Gilman A. G. (1986) Antisera of designed specificity for subunits of guanine nucleotide-binding regulatory proteins. Proc. Natl Acad. Sci. USA 83, 265-269.
34. Munson P. J. and Rodbard D. (1980) A versatile computerized approach for characterization of ligand binding systems. Anal. Biochem. 107, 220-239.
35. Nag S. and Tang F. (2001) The effect of age on the response of the rat brains to continuous β-amyloid infusion. Brain Res. 889, 303-307.
36. Nag S., Yee B. K. and Tang F. (1999) Reduction in somatostatin and substance P levels and choline acetyltransferase activity in the cortex and hippocampus of the rat after chronic intracerebroventricular infusion of β-amyloid (1-40). Brain Res. Bull. 50, 251-262.
37. Niikura T., Hashimoto Y., Okamoto T. et al. (2001) Insulin-like growth factor 1 (IGF-I) protects cells from apoptosis by Alzheimer's V642I mutant amyloid precursor protein through IGF-I receptor in an IGF-binding protein-sensitive manner. J. Neurosci. 21, 1902-1910.
38. Nitta A., Itoh A., Hasegawa T. and Nabeshima T. (1994) β-Amyloid protein-induced Alzheimer's disease animal model. Neurosci. Lett. 170, 63-66.
39. Patel Y. C. and Reichlin S. (1978) Somatostatin in hypothalamus, extrahypothalamic brain and peripheral tissues of the rat. Endocrinology 102, 523-530.
40. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, Sydney.
41. Pichler R., Maschek W., Crespillo C., Esteva I. and Soriguer F. (2002) Is there a gender difference of somatostatin-receptor density in the human brain?. Neuroendocrinol. Lett. 23, 440-441.
42. Reinhardt R. R. and Bondy C. A. (1994) Insulin-like growth factors cross the blood-brain barrier. Endocrinology 135, 1753-1761.
43. Reinikainen K. J., Soininen H. and Riekkinen P. J. (1990) Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy. J. Neurosci. Res. 27, 576-586.
44. Reisine T. and Bell G. I. (1995) Molecular biology of somatostatin receptors. Endocr. Rev. 16, 427-442.
45. Reubi J. C., Perrin M. H., Rivier J. E. and Vale V. (1981) High affinity binding sites for the somatostatin-28 analogue in rat brain. Life. Sci. 28, 2191-2198.
46. Ryder J., Su Y. and Ni B. (2004) Akt/GSK3β serine/threonine kinases: evidence for a signalling pathway mediated by familial Alzheimer's disease mutations. Cell Signal. 16, 187-200.
47. Sato H., Ota Z. and Ogawa N. (1991) Somatostatin receptors in the senescent rat brain: a quantitative autoradiographic study. Regul. Pept. 33, 81-92.
48. Schettini G., Florio T., Meucci O., Landolfi E., Grimaldi M., Ventra C. and Marino A. (1989) Somatostatin inhibition of adenylate cyclase activity in different brain areas. Brain Res. 492, 65-71.
49. Torres-Alemán I., Barrios V. and Berciano J. (1998) The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis. Neurology 50, 772-776.
50. Ulas J., Brunner L. C., Nguyen L. and Cotman C. W. (1993) Reduced density of adenosine A1 receptors and preserved coupling of adenosine A1 receptors to G proteins in Alzheimer hippocampus: a quantitative autoradiographic study. Neuroscience 52, 843-854.
51. Varadarajan S., Kanski J., Aksenova M., Lauderback C. and Butterfield A. (2001) Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's Aβ (1-42) and Aβ (25-35). J. Am. Chem. Soc. 123, 5625-5631.
52. Vitolo O. V., Sant'Angelo A., Costanzo V., Battaglia F., Arancio O. and Shelanski M. (2002) Amyloid β-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl Acad. Sci. USA 99, 13 217-13 221.
53. Wei W., Wang X. and Kusiak J. W. (2002) Signaling events in amyloid beta-peptide-induced neuronal death and insulin-like growth factor I protection. J. Biol. Chem. 277, 17 649-17 656.
54. Yamada M., Tanabe K., Wada K., Shimoke K., Ishikawa Y., Ikeuchi T., Koizumi S. and Hatanaka H. (2001) Differences in survival-promoting effects and intracellular signaling properties of BDNF and IGF-I in cultured cerebral cortical neurons. J. Neurochem. 78, 940-951.
55. Zheng W. H. and Quirion R. (2004) Comparative signaling pathways of insulin-like growth factor-1 and brain-derived neurotrophic factor in hippocampal neurons and the role of the PI3 kinase pathway in cell survival. J. Neurochem. 89, 844-852.